ATE96840T1 - Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen. - Google Patents

Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen.

Info

Publication number
ATE96840T1
ATE96840T1 AT88311421T AT88311421T ATE96840T1 AT E96840 T1 ATE96840 T1 AT E96840T1 AT 88311421 T AT88311421 T AT 88311421T AT 88311421 T AT88311421 T AT 88311421T AT E96840 T1 ATE96840 T1 AT E96840T1
Authority
AT
Austria
Prior art keywords
vectors
human protein
compositions useful
direct expression
activated human
Prior art date
Application number
AT88311421T
Other languages
English (en)
Inventor
Nils Ulrik Bang
Hartmut Josef Ehrlich
Brian William Grinnell
Stanley Richard Jaskunas Jr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE96840T1 publication Critical patent/ATE96840T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AT88311421T 1987-12-04 1988-12-02 Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen. ATE96840T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/129,027 US4992373A (en) 1987-12-04 1987-12-04 Vectors and compounds for direct expression of activated human protein C
EP88311421A EP0319312B1 (de) 1987-12-04 1988-12-02 Für die direkte Expression von aktiviertem menschlichen Protein-C verwendbare Vektoren und Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE96840T1 true ATE96840T1 (de) 1993-11-15

Family

ID=22438133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88311421T ATE96840T1 (de) 1987-12-04 1988-12-02 Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen.

Country Status (20)

Country Link
US (1) US4992373A (de)
EP (1) EP0319312B1 (de)
JP (1) JP2749083B2 (de)
KR (1) KR970009081B1 (de)
CN (1) CN1035527A (de)
AR (1) AR245217A1 (de)
AT (1) ATE96840T1 (de)
AU (1) AU610301B2 (de)
CA (1) CA1339938C (de)
DE (1) DE3885419T2 (de)
DK (1) DK672788A (de)
ES (1) ES2059538T3 (de)
HU (1) HU209587B (de)
IE (1) IE61627B1 (de)
IL (1) IL88559A (de)
MX (1) MX166847B (de)
NZ (1) NZ227177A (de)
PT (1) PT89135B (de)
RU (1) RU1830081C (de)
ZA (1) ZA889033B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6437298A (en) * 1987-08-04 1989-02-07 Hiroshi Okamoto Production of c-terminal amidated peptide
DE69004964T2 (de) * 1989-08-11 1994-03-24 Zymogenetics Inc Zellenzuchtverfahren für die produktion von aktiviertem protein-c.
WO1991009960A1 (en) * 1989-12-29 1991-07-11 Zymogenetics, Inc. Hybrid protein c
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
JP4236698B2 (ja) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US6262336B1 (en) 1991-01-11 2001-07-17 American Red Cross Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
ATE211177T1 (de) * 1991-01-11 2002-01-15 American Nat Red Cross Expression von aktivem menschlichem protein c im milchdrüsengewebe transgener tiere
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
US5464934A (en) * 1993-05-14 1995-11-07 Mallinckrodt Medical, Inc. Metal chelates as spacer compounds in biologically active peptides
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
US5698444A (en) * 1993-12-23 1997-12-16 Eli Lilly And Company Serotonin receptor protein and related nucleic acid compounds
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US5723755A (en) * 1995-05-16 1998-03-03 Francis E. Lefaivre Large scale production of human or animal proteins using plant bioreactors
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
US5905185A (en) * 1995-11-30 1999-05-18 Ppl Therapeutics Protein C production in non-human transgenic mammals
ID23172A (id) 1997-04-28 2000-03-23 Lilly Co Eli Metode yang diperbaiki untuk pengolahan protein c teraktivasi
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
KR20010013413A (ko) * 1997-06-05 2001-02-26 피터 지. 스트링거 혈전성 질환의 치료 방법
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6103524A (en) * 1998-07-30 2000-08-15 Eli Lilly And Company Metabotropic glutamate receptor protein and nucleic acid
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
EP1124573A1 (de) 1998-10-22 2001-08-22 Eli Lilly And Company Behandlung von sepsis
BR9915317A (pt) 1998-11-13 2001-08-07 Lilly Co Eli Método de tratar trombocitopenia induzida por heparina
JP2002530353A (ja) 1998-11-20 2002-09-17 イーライ・リリー・アンド・カンパニー ウイルス性出血熱の処置法
DE69905489T2 (de) 1998-11-23 2003-09-11 Eli Lilly And Co., Indianapolis Protein c zur behandlung von sichelzellanämie und thalassämie
WO2000066709A2 (en) * 1999-04-30 2000-11-09 Ortho-Mcneil Pharmaceutical, Inc. Zymogen activation system
US6420157B1 (en) 1999-04-30 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Zymogen activation system
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
AU1751801A (en) * 1999-11-19 2001-05-30 Eli Lilly And Company Protein c derivatives
US6841371B2 (en) 2000-02-02 2005-01-11 Eli Lilly And Company Protein C derivatives
EP1263943A1 (de) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivate
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2001089558A2 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
JP4071105B2 (ja) * 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインｃまたは活性化プロテインｃ様分子
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
WO2003024398A2 (en) 2001-09-19 2003-03-27 Oklahoma Medical Research Foundation Treatment of sepsis with tafi
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
EP1485121A4 (de) * 2002-03-08 2007-11-07 Lilly Co Eli Aktivierte protein-c-formulierungen
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1773371A4 (de) * 2004-07-23 2009-12-30 Univ Rochester Aktiviertes protein c hemmt unerwünschte effekte von plasminogenaktivator im gehirn
KR20080021682A (ko) * 2005-05-24 2008-03-07 아베스타 겐그레인 테크놀로지스 피브이티 리미티드 패혈증 치료용 재조합 활성화 인간 단백질 ｃ의 제조를위한 코돈 최적화를 포함하는 방법
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
BRPI0613137A2 (pt) * 2005-06-24 2010-12-21 Drugrecure Aps administração em vias aéreas de proteìna c ativada em condições inflamatórias afetando o trato respiratório
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
AU2009329493B2 (en) 2008-12-19 2014-09-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
RU2469093C2 (ru) * 2008-12-19 2012-12-10 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
EP2199387A1 (de) 2008-12-19 2010-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Serinproteasederivate und deren Verwendung zur Vorbeugung und/oder Behandlung von Blutgerinnungsstörungen
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
DK3811777T3 (da) * 2019-10-27 2024-09-02 Shanghai Raas Blood Products Co Ltd Genetisk modificerede ikke-humane dyr humaniseret til protein c
WO2023171719A1 (ja) * 2022-03-08 2023-09-14 学校法人自治医科大学 活性化プロテインｃ配列

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4603105A (en) * 1982-05-27 1986-07-29 Kaplan Donald A Efficient screening methods for low probability variants
GB8327860D0 (en) * 1983-10-18 1983-11-16 Fujisawa Pharmaceutical Co Monoclonal antiprotein c antibody
US4617265A (en) * 1984-09-19 1986-10-14 Board Of Regents, University Of Texas System Colony blot assay for enterotoxigenic bacteria
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
ATE93272T1 (de) * 1985-06-27 1993-09-15 Zymogenetics Inc Expression von protein c.
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
GB8728837D0 (en) * 1987-12-10 1988-01-27 Eaton Corp Semi-automatic mechanical transmission control and control and control method
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c

Also Published As

Publication number Publication date
DE3885419T2 (de) 1994-03-31
HU209587B (en) 1994-08-29
PT89135A (pt) 1989-12-29
RU1830081C (ru) 1993-07-23
IL88559A (en) 1994-02-27
AU2650988A (en) 1989-06-08
US4992373A (en) 1991-02-12
PT89135B (pt) 1994-04-29
NZ227177A (en) 1990-07-26
DK672788A (da) 1989-07-28
EP0319312A2 (de) 1989-06-07
KR890010199A (ko) 1989-08-07
CN1035527A (zh) 1989-09-13
HUT50497A (en) 1990-02-28
ZA889033B (en) 1990-08-29
DK672788D0 (da) 1988-12-02
AU610301B2 (en) 1991-05-16
EP0319312A3 (en) 1990-09-19
IE61627B1 (en) 1994-11-16
KR970009081B1 (en) 1997-06-05
JPH022372A (ja) 1990-01-08
IL88559A0 (en) 1989-07-31
IE883612L (en) 1989-06-04
ES2059538T3 (es) 1994-11-16
DE3885419D1 (de) 1993-12-09
EP0319312B1 (de) 1993-11-03
AR245217A1 (es) 1993-12-30
JP2749083B2 (ja) 1998-05-13
CA1339938C (en) 1998-07-07
MX166847B (es) 1993-02-09

Similar Documents

Publication Publication Date Title
ATE96840T1 (de) Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen.
DE3583392D1 (de) Carbonatapatit enthaltendes mittel und die verwendung von carbonatapatit fuer implantate.
DE68927835D1 (de) Ultraschallbehandlung von Tieren
IT1219613B (it) Composizione per il condizionamento e la lucentezza dei capelli
DE3855489D1 (de) Behandlung von Hautfalten
FI900808A7 (fi) Ihmisen mannoosia sitova proteiini
PT86946A (pt) Skin care compositions
IT1190313B (it) Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
DK90089A (da) Hudbehandlingspraeparat
DK96787D0 (da) Human vaevs-plasminogenaktivator
DE68913739D1 (de) Kosmetische und hautbehandlungs-zusammensetzungen.
IT8868118A0 (it) Composizione e procedimento per il trattamento e la cura dei capelli
PT87554A (pt) Didinfecting and sterilizing composition
DE3850433D1 (de) Allergiebehandlung und Zusammensetzung dafür.
DE3672283D1 (de) Konditionierungsmittel fuer die behandlung von basismaterialien.
DE3852625D1 (de) Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C.
IT1227671B (it) Procedimento e dispositivo per la fabbricazione di copertine di libri
DK444288D0 (da) Humant reg - protein
DE68905238D1 (de) Linearisierungsverfahren fuer gleichspannungswandler und durchfuehrung des verfahrens.
FR2633516B1 (fr) Composition cosmetique pour le traitement des peaux sensibles deshydratees
IT8820276A0 (it) Procedimento per la sintesi di ossalil_ ed ossamil_idrazidi.
IT1245733B (it) Procedimento per il trattamento di magnesio e dispositivo per la sua attuazione
IT1237845B (it) Procedimento e dispositivo per la raccolta silenziosa di prodotti longitudinalmente estesi
DE3769332D1 (de) Derivate von pyrido-menadion-additionsprodukten und verwendungen davon.
DK32689A (da) Teicoplaninhydrazider samt fremstilling og anvendelse deraf

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee